These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36400254)

  • 1. Predicting in vitro lung deposition behavior of combined dry powder inhaler via rheological properties.
    Li J; Ma S; Sun Y; Song R; Cai B; Li H; Chen Y; Zhang X; Guan J; Mao S
    Eur J Pharm Biopharm; 2022 Dec; 181():195-206. PubMed ID: 36400254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the influence of magnesium stearate content and mixing modality on the rheological properties and in vitro aerosolization of dry powder inhaler.
    Li J; Ma S; He X; Sun Y; Zhang X; Guan J; Mao S
    Int J Pharm; 2023 Jul; 642():123179. PubMed ID: 37364785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the potential influence of drug charge on downstream deposition behaviour of DPI powders.
    Sun Y; Cui Z; Sun Y; Qin L; Zhang X; Liu Q; Shen X; Yu D; Mao S
    Int J Pharm; 2020 Oct; 588():119798. PubMed ID: 32828976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elucidation of lactose fine size and drug shape on rheological properties and aerodynamic behavior of dry powders for inhalation.
    Sun Y; Yu D; Li J; Zhao J; Feng Y; Zhang X; Mao S
    Eur J Pharm Biopharm; 2022 Oct; 179():47-57. PubMed ID: 36029939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidating the Effect of Fine Lactose Ratio on the Rheological Properties and Aerodynamic Behavior of Dry Powder for Inhalation.
    Sun Y; Qin L; Li J; Su J; Song R; Zhang X; Guan J; Mao S
    AAPS J; 2021 Apr; 23(3):55. PubMed ID: 33856568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the influence of drug content on DPI powder properties and potential prediction of pulmonary drug deposition.
    Sun Y; Qin L; Liu C; Su J; Zhang X; Yu D; Guo C; Lu H; Li L; Xiong W; Mao S
    Int J Pharm; 2020 Feb; 575():119000. PubMed ID: 31893544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
    Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG
    Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel dry powder inhaler formulation containing antibiotic using combined technology to improve aerodynamic properties.
    Ambrus R; Benke E; Farkas Á; Balásházy I; Szabó-Révész P
    Eur J Pharm Sci; 2018 Oct; 123():20-27. PubMed ID: 30016647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols.
    Muralidharan P; Mallory EK; Malapit M; Phan H; Ledford JG; Hayes D; Mansour HM
    RSC Adv; 2020 Nov; 10(68):41846-41856. PubMed ID: 33391731
    [No Abstract]   [Full Text] [Related]  

  • 12. A quantitative approach to predicting lung deposition profiles of pharmaceutical powder aerosols.
    Yaqoubi S; Chan HK; Nokhodchi A; Dastmalchi S; Alizadeh AA; Barzegar-Jalali M; Adibkia K; Hamishehkar H
    Int J Pharm; 2021 Jun; 602():120568. PubMed ID: 33812969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW; Schneider M; Morrical BD; Imanidis G
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-time and modular approach for quick detection and mechanism exploration of DPIs with different carrier particle sizes.
    Cui Y; Huang Y; Zhang X; Lu X; Xue J; Wang G; Hu P; Yue X; Zhao Z; Pan X; Wu C
    Acta Pharm Sin B; 2022 Jan; 12(1):437-450. PubMed ID: 35127397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.
    Sommerfeld M; Cui Y; Schmalfuß S
    Eur J Pharm Sci; 2019 Feb; 128():299-324. PubMed ID: 30553814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation into alternative sugars as potential carriers for dry powder formulation of budesonide.
    Momin MN; Hedayati A; Nokhodchi A
    Bioimpacts; 2011; 1(2):105-11. PubMed ID: 23678414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of drug alone and carrier-based GLP-1 dry powder inhaler formulations.
    Babenko M; Alany RG; Calabrese G; Kaialy W; ElShaer A
    Int J Pharm; 2022 Apr; 617():121601. PubMed ID: 35181460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of dry powder aerosolization mechanisms in different channel designs.
    Chen L; Heng RL; Delele MA; Cai J; Du DZ; Opara UL
    Int J Pharm; 2013 Nov; 457(1):143-9. PubMed ID: 24055441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery.
    Liu S; Watts AB; Du J; Bui A; Hengsawas S; Peters JI; Williams RO
    Eur J Pharm Biopharm; 2015 Oct; 96():132-42. PubMed ID: 26220015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.